Currently, lifirafenib in combination with the MEK inhibitor mirdametinib is being evaluated in a phase I clinical trial (NCT03905148, Table 1) with preliminary findings indicating a favorable safety profile and showing evidence of antitumor activity, including in NSCLC patients harboring KRAS, NRAS, and BRAF mutations. Here, MAP2K7 is linked to non-small cell lung carcinoma.